Top-News
Pharmazeutika USA

Akebia Therapeutics Inc Aktie

Aktie
WKN:  A1XF0S ISIN:  US00972D1054 US-Symbol:  AKBA
2,475 $
+0,08 $
+3,34%
2,1899 € 20:41:41 Uhr
Depot/Watchlist
Aktienanzahl *
218,18 Mio.
Marktkapitalisierung *
464,12 Mio. €
Streubesitz
68,25%
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 17.12.2024

Akebia Therapeutics Inc News

13.01.25 - PR Newswire
Akebia Therapeutics Announces Multiple Positive Business Updates
Akebia Therapeutics Announces Multiple Positive Business Updates PR Newswire
02.01.25 - PR Newswire
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
18.12.24 - PR Newswire
Akebia Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Akebia Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference PR Newswire
03.12.24 - PR Newswire
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
03.12.24 - PR Newswire
U.S. Renal Care Enrolled First Patients in the VOICE Collaborative Clinical Trial of Vafseo® (vadadustat) for CKD Patients on Dialysis
U.S. Renal Care Enrolled First Patients in the VOICE Collaborative Clinical Trial of Vafseo® (vadadustat) for CKD Patients on Dialysis PR Newswire
25.11.24 - PR Newswire
Akebia Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference
Akebia Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference PR Newswire
14.11.24 - PR Newswire
Vadadustat Alternative Dosing Study Results Published in the American Journal of Kidney Disease
Vadadustat Alternative Dosing Study Results Published in the American Journal of Kidney Disease PR Newswire
12.11.24 - PR Newswire
Akebia Therapeutics to Present at the Jefferies London Healthcare Conference
Akebia Therapeutics to Present at the Jefferies London Healthcare Conference PR Newswire
07.11.24 - PR Newswire
Akebia Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Akebia Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights PR Newswire
01.11.24 - PR Newswire
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
01.11.24 - PR Newswire
Akebia Therapeutics to Report Third Quarter 2024 Financial Results and Discuss Recent Business Highlights
Akebia Therapeutics to Report Third Quarter 2024 Financial Results and Discuss Recent Business Highlights PR Newswire
22.10.24 - PR Newswire
Akebia Therapeutics Signs Commercial Supply Contract with Leading Dialysis Organization to Enable Access to Vafseo® (vadadustat) for Patients on Dialysis
Akebia Therapeutics Signs Commercial Supply Contract with Leading Dialysis Organization to Enable Access to Vafseo® (vadadustat) for Patients on Dialysis PR Newswire
15.10.24 - PR Newswire
Akebia Therapeutics Announces Seven Poster Presentations at ASN Kidney Week 2024
Akebia Therapeutics Announces Seven Poster Presentations at ASN Kidney Week 2024 PR Newswire
10.10.24 - PR Newswire
CMS Grants TDAPA Reimbursement for Vafseo® (vadadustat) beginning January 1, 2025
CMS Grants TDAPA Reimbursement for Vafseo® (vadadustat) beginning January 1, 2025 PR Newswire
07.10.24 - PR Newswire
Akebia Therapeutics and U.S. Renal Care Sign Commercial Supply Contract to Enable Access to Vafseo® (vadadustat) for Patients on Dialysis
Akebia Therapeutics and U.S. Renal Care Sign Commercial Supply Contract to Enable Access to Vafseo® (vadadustat) for Patients on Dialysis PR Newswire
01.10.24 - PR Newswire
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
05.09.24 - PR Newswire
Akebia Therapeutics and U.S. Renal Care Initiate the VOICE Trial of Vafseo® (vadadustat) for Patients on Dialysis
Akebia Therapeutics and U.S. Renal Care Initiate the VOICE Trial of Vafseo® (vadadustat) for Patients on Dialysis PR Newswire
03.09.24 - PR Newswire
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
26.08.24 - PR Newswire
Akebia Therapeutics to Present at Upcoming Investor Conferences
Akebia Therapeutics to Present at Upcoming Investor Conferences PR Newswire
08.08.24 - PR Newswire
Akebia Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
Akebia Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights PR Newswire

Newssuche

Videos

newspaper
30.04.25 +22,47%
Technical Trading: Cotton Long Chance
Cotton Long Typ: Turbo Open End WKN: VP6N8D Hebel: 3,80 Laufzeit: OpenEnd Einstieg: Market ... Mehr »